Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Crotamiton is a topical scabicidal and antipruritic agent used primarily for the treatment of scabies and relief of pruritus (itching) associated with various skin conditions. It is available as a cream or lotion for topical use only. The drug acts as an anti-parasite by killing the mites that cause scabies, likely through disruption of their nerves and muscles. Its antipruritic effect is attributed to inhibition of sensory ion channels such as transient receptor potential vanilloid 4 (TRPV4), which are expressed in the skin and primary sensory neurons. Additionally, crotamiton relieves itching by producing a cooling effect on evaporation from the skin (counter-irritation). The precise mechanism underlying its scabicidal action remains unknown[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on crotamiton.